Literature DB >> 30016928

SLE mortality remains disproportionately high, despite improvements over the last decade.

R R Singh1, E Y Yen1.   

Abstract

Despite a marked improvement in 10-year survival for systemic lupus erythematosus (SLE) patients over the past five decades, mortality rates from SLE remain high compared to those in the general population. SLE was also among the leading causes of death in young women in the United States during 2000-2015. However, it is encouraging that SLE mortality rates and the ratios of SLE mortality rates to non-SLE mortality rates have decreased every year since the late 1990s. Despite this improvement, disparities in SLE mortality persist according to sex, race, age, and place of residence. Furthermore, demographic and geographic variables seem to modify the effect of each other in influencing SLE mortality, leading to interactions between sex/race/ethnicity-associated factors and geographic differences. In other words, individuals of the same sex/race/ethnicity had differences in SLE mortality depending on where they lived. These observations highlight SLE as an important public health issue. The recognition of SLE as a leading cause of death in the general population might spur targeted public health programs and research funding to address the high lupus mortality.

Entities:  

Keywords:  Geographic region; leading cause of death; mortality; race; sex; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 30016928      PMCID: PMC6082727          DOI: 10.1177/0961203318786436

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  24 in total

1.  Plaquenil in the treatment of lupus erythematosus.

Authors:  J F MULLINS; F L WATTS; C J WILSON
Journal:  J Am Med Assoc       Date:  1956-06-30

2.  Natural history of lupus erythematosus disseminatus.

Authors:  R A JESSAR; R W LAMONT-HAVERS; C RAGAN
Journal:  Ann Intern Med       Date:  1953-04       Impact factor: 25.391

3.  Cyclophosphamide in lupus nephritis: a controlled trial.

Authors:  A D Steinberg; H B Kaltreider; P J Staples; E J Goetzl; N Talal; J L Decker
Journal:  Ann Intern Med       Date:  1971-08       Impact factor: 25.391

4.  Azathioprine in the treatment of systemic lupus erythematosus. A controlled study.

Authors:  M Sztejnbok; A Stewart; H Diamond; D Kaplan
Journal:  Arthritis Rheum       Date:  1971 Sep-Oct

5.  Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study.

Authors:  Maria D Alonso; Javier Llorca; Francisco Martinez-Vazquez; Jose A Miranda-Filloy; Teresa Diaz de Teran; Trinidad Dierssen; Tomas R Vazquez-Rodriguez; Ines Gomez-Acebo; Ricardo Blanco; Miguel A Gonzalez-Gay
Journal:  Medicine (Baltimore)       Date:  2011-09       Impact factor: 1.889

6.  Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus.

Authors:  Murray B Urowitz; Dafna D Gladman; Brian D M Tom; Dominique Ibañez; Vernon T Farewell
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

7.  Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus.

Authors:  A N Malaviya; R R Singh; R Sindhwani; Y N Singh; R K Ahujà; U N Bhuyan; S D Khare; A Kumar; R Malaviya; P C Negi
Journal:  Indian J Med Res       Date:  1992-04       Impact factor: 2.375

8.  Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

Authors:  Marko Yurkovich; Kateryna Vostretsova; Wenjia Chen; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

9.  Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

Authors:  K M Uramoto; C J Michet; J Thumboo; J Sunku; W M O'Fallon; S E Gabriel
Journal:  Arthritis Rheum       Date:  1999-01

10.  Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis.

Authors:  Y H Lee; S J Choi; J D Ji; G G Song
Journal:  Lupus       Date:  2016-01-24       Impact factor: 2.911

View more
  14 in total

Review 1.  Cardiovascular Outcomes in Systemic Lupus Erythematosus.

Authors:  Shrilekha Sairam; Amit Sureen; Jesus Gutierrez; The Q Dang; Kunal Mishra
Journal:  Curr Cardiol Rep       Date:  2022-01-13       Impact factor: 2.931

Review 2.  Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus.

Authors:  Shilpa Arora; Jinoos Yazdany
Journal:  Rheum Dis Clin North Am       Date:  2020-09-09       Impact factor: 2.670

Review 3.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

4.  Splicing factor SRSF1 limits IFN-γ production via RhoH and ameliorates experimental nephritis.

Authors:  Takayuki Katsuyama; Hao Li; Suzanne M Krishfield; Vasileios C Kyttaris; Vaishali R Moulton
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

Review 5.  Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.

Authors:  Marilyn E Allen; Violeta Rus; Gregory L Szeto
Journal:  Trends Mol Med       Date:  2020-10-09       Impact factor: 11.951

6.  Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project.

Authors:  Susan Manzi; Sandra Raymond; Karin Tse; Yaritza Peña; Annick Anderson; Kathleen Arntsen; Sang-Cheol Bae; Ian Bruce; Thomas Dörner; Kenneth Getz; Leslie Hanrahan; Amy Kao; Eric Morand; Brad Rovin; Laura Eve Schanberg; Joan M Von Feldt; Victoria P Werth; Karen Costenbader
Journal:  Lupus Sci Med       Date:  2019-07-19

Review 7.  Update on the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond.

Authors:  Young-Chang Kwon; Sehwan Chun; Kwangwoo Kim; Anselm Mak
Journal:  Cells       Date:  2019-09-30       Impact factor: 6.600

8.  The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research.

Authors:  Karin Tse; Sanjyot Sangodkar; Lauren Bloch; Kathleen Arntsen; Sang-Cheol Bae; Ian N Bruce; Erin Connolly-Strong; Karen H Costenbader; Bradley Dickerson; Thomas Dörner; Sydney Evans; Kenneth Kalunian; Amy H Kao; Susan Manzi; Eric F Morand; Sandra C Raymond; Brad H Rovin; Laura Eve Schanberg; Joan M Von Feldt; Victoria P Werth; Angel Williams Derricott; David Zook; Timothy Franson; Kenneth Getz; Yaritza Peña; Leslie M Hanrahan
Journal:  Lupus Sci Med       Date:  2021-02

9.  Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons - California, 2007-2017.

Authors:  Milena A Gianfrancesco; Maria Dall'Era; Louise B Murphy; Charles G Helmick; Jing Li; Stephanie Rush; Laura Trupin; Jinoos Yazdany
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-02-19       Impact factor: 17.586

10.  Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients.

Authors:  Sofia Ajeganova; Thomas Gustafsson; Linnea Lindberg; Ingiäld Hafström; Johan Frostegård
Journal:  Lupus Sci Med       Date:  2020-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.